In the episode, host Bob Chew is joined by Michelle Vuolo, Head of Quality at Tulip Interfaces and co-lead of the ISPE Good Practice Guide: Validation 4.0, and Victor de Oliveira Silva Ferreira, Project Manager for PEQMS – Implementation of Electronic Systems for the Quality Management System at Instituto de Tecnologia em Imunobiológico/Fundação Oswaldo Cruz and a member of the Validation 4.0 Guide team. Together, they offer a practical and experience-based perspective on how validation must evolve to keep pace with digital pharma.
Why Validation 4.0, and Why Now?
Validation 4.0 did not emerge as a response to a single technology or regulatory change. As Vuolo explains, it grew out of a broader realization: while validation practices have remained largely static, the systems they are meant to control have become increasingly dynamic.
Traditional validation approaches, often centered on predefined protocols, paper-based documentation, and one-time qualification events, struggle to reflect the reality of modern manufacturing environments. Digital systems generate vast amounts of data across the lifecycle, yet much of that data remains underutilized once validation is “completed.”
Validation 4.0 reframes validation not as a discrete activity, but as a continuous demonstration of control, grounded in long-established principles such as Quality Risk Management and Quality by Design. Rather than replacing regulatory expectations, it seeks to operationalize them more effectively in a digital world.
Moving Beyond the “Three-Run” Mindset
One of the most familiar constructs in traditional validation is the expectation of a fixed number of qualification runs; often referred to as the “golden three.” While historically useful, Vuolo notes that this approach has limitations. Three runs are rarely statistically meaningful, nor do they adequately capture process variability over time.
Validation 4.0 shifts the question from “How many runs did we execute?” to “How have we demonstrated control of the process?” That distinction is critical. Control is not proven by repetition alone, but by understanding critical process parameters, identifying appropriate controls, and continuously verifying their effectiveness.
In this model, validation evidence is built incrementally across development, scale-up, and commercial manufacturing. The result is not a static validation package, but a living body of evidence that evolves alongside the process itself.
Digital Tools as Enablers, Not the Starting Point
While digital technologies play a central role in Validation 4.0, both speakers emphasize that technology is not the starting point. The foundation remains strong quality principles and a clear understanding of risk.
Ferreira highlights how digital ecosystems, integrating manufacturing execution systems, laboratory information management systems, and electronic quality systems, enable data to flow across traditionally siloed functions. This integration supports real-time visibility into process performance and control effectiveness, making it possible to assess validation status at any point in time.
Importantly, digital tools also help address the inherent subjectivity of many quality risk management activities. By using data-driven insights and feedback loops, teams can move beyond static risk assessments toward continuous learning: adjusting controls based on real evidence rather than assumptions.
Continuous Validation Across the Lifecycle
Another core insight from the episode is the idea of scalability across lifecycle phases. Validation 4.0 does not eliminate development, qualification, or ongoing verification, but it changes how rigor is applied at each stage.
Ferreira explains that when data and controls are established early, organizations gain confidence to scale validation activities more efficiently as products move through clinical phases and into commercialization. Digital visibility allows teams to tailor effort based on risk, rather than applying the same level of documentation and testing everywhere.
This lifecycle-based approach aligns closely with existing regulatory guidance, including principles already embedded in Annex 15. In many ways, Validation 4.0 reflects what regulators have been encouraging for years: risk-based decision-making, continuous verification, and meaningful use of data.
A Shift in Culture as Much as Process
Perhaps the most significant takeaway from the conversation is that Validation 4.0 represents a cultural shift. Moving away from static validation packages requires organizations to rethink how success is measured and how data is used.
As Vuolo observes, many validation professionals have historically focused on producing documentation rather than demonstrating control. Validation 4.0 challenges that mindset, placing emphasis on patient safety, product quality, and real-time understanding over procedural compliance alone.
This shift has tangible benefits. By reducing non–value-added activities and focusing effort where risk truly lies, teams can respond more quickly to change, support innovation, and accelerate time to value, without compromising compliance.
Why This Conversation Matters
This episode of ISPE Podcast: Shaping the Future of Pharma offers more than a conceptual discussion: it provides grounded insights from experts directly involved in defining the Validation 4.0 framework. For professionals in quality, validation, engineering, manufacturing, or digital transformation, the conversation offers a clear message: validation must evolve, and the tools to do so are already within reach.
Listen to the full episode.
Learn more about ISPE Good Practice Guide: Validation 4.0
